All In Biotech

Drug Trial Radar · NCT02980692

Efficacy and Safety Study of SUNPG1623

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Jan 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 391 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

391

Actual

Start

Apr 19, 2017

Primary completion

Mar 1, 2019

Study completion Sep 24, 2019

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Conditions

  • Active Psoriatic Arthritis

Interventions

  • SUNPG1623 IDrug

    injection

  • SUNPG1623 IIDrug

    injection

  • SUNPG1623 IIIDrug

    injection

  • SUNPG1623 IVDrug

    injection

  • PLACEBODrug

    injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Achieve American College of Rheumatology20 Response RateTime frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SPARC Site 1

    Middleburg Heights, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.